Search
Search Results
-
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
BackgroundBreast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen...
-
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
ObjectiveTo investigate CITED1 as a potential biomarker of anti-endocrine response and breast cancer recurrence, given its previously determined role...
-
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone...
-
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of breast cancers (BC). Approximately 60–70% of HER2+ BC co-express...
-
Immune landscape of breast tumors with low and intermediate estrogen receptor expression
Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also...
-
Nanomedicine in therapeutic warfront against estrogen receptor–positive breast cancer
Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide. Almost 70–80% of cases of BC are curable at the early...
-
Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival
BackgroundTriple negative BCa (TNBC) is defined by a lack of expression of estrogen (ERα), progesterone (PgR) receptors and human epidermal growth...
-
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
TP53 and estrogen receptor (ER) are essential in breast cancer development and progression, but TP53 status (by DNA sequencing or protein expression)...
-
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression...
-
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer
Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of...
-
Receptor conversion and survival in breast cancer liver metastases
BackgroundBreast cancer liver metastases (BCLM) is a common cause of breast cancer-related death. The prognostic and predictive value of receptor...
-
Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients
Estrogen receptor-α ( ESR1 ) single nucleotide polymorphisms (SNPs) have been related to breast cancer (BC) susceptibility. In this retrospective study...
-
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
Although 1% is the recommended cut-off to define estrogen receptor (ER) positivity, a 10% cut-off is often used in clinical practice for therapeutic...
-
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
BackgroundHER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to...
-
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is controversial, constraining implementation of...
-
KIF18A as a potential biomarker to distinguish different breast cancer subtypes based on receptor status
The inhibition of KIF18A selectively reduces the viability of chromosomally unstable cancers due to increased mitotic vulnerability. KIF18A ...
-
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study
Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This...
-
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
BackgroundReal-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in...
-
Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan
BackgroundBreast cancer (BC) is one of the major causes of death worldwide. It is the most common cause of death before the age of 70 years. The...
-
The impact of CBP expression in estrogen receptor-positive breast cancer
BackgroundThe development of new biomarkers with diagnostic, prognostic and therapeutic prominence will greatly enhance the management of breast...
